Treatment of acute monoblastic leukaemia by combination of recombinant human macrophage colony-stimulating factor and low dose of ara-C.
We present a patient with acute monoblastic leukaemia (AMoL) who achieved a complete remission on combination therapy with macrophage colony-stimulating factor (M-CSF) and low dose of cytosine arabinoside (ara-C). This 26-year-old man was admitted with a relapse of AMoL which proved refractory to several chemotherapeutic regimens. To kill dormant leukaemic cells, we administered 20 mg/m2 ara-C by continuous intravenous infusion and 800 x 10(4) unit M-CSF by 30 min drip intravenous infusion together for 14 d. The blasts disappeared, followed by a recovery of normal blood cells. The patient continued the complete remission for 5 months. This observation suggests that a combination M-CSF and a low dose of ara-C may be useful in treating some patients with AMoL.
Kitano
K
K
Second Department of Internal Medicine, Shinshu University School of Medicine, Japan.
Kobayashi
H
H
Maeyama
H
H
Miyabayashi
H
H
Furuta
S
S
D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003561:Cytarabine / Q000008:administration & dosage; D006801:Humans; D007948:Leukemia, Monocytic, Acute / Q000188:drug therapy*; D016173:Macrophage Colony-Stimulating Factor / Q000008:administration & dosage; D008297:Male; D011994:Recombinant Proteins / Q000008:administration & dosage
D011994:Recombinant Proteins; D003561:Cytarabine; D016173:Macrophage Colony-Stimulating Factor